Idorsia's ACT-541468 meets primary endpoint in adult and elderly patients with insomnia

31 July 2017

Swiss biotech firm Idorsia (SIX: IDIA) has released positive results for the comprehensive Phase II program with the dual orexin receptor antagonist ACT-541468 (DORA) in insomnia, with zolpidem as an active reference.

The program comprised two placebo-controlled dose-response studies to evaluate the safety and efficacy of ACT-541468 in adult and elderly patients with insomnia, with a total of 418 patients participating in the trials.

Idorsia’s shares rose 9.15% to 17.90 Swiss francs on Friday following the announcement. The company is the spin-out from Actelion following the $30 billion acquisition of the Swiss biotech major by Johnson & Johnson which debuted on June 16 at 10 francs a share, and on the first day of trading reached 13 francs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK